ABBV-744 IN COMBINATION WITH IMMUNOTHERAPY - AN OVERVIEW

In Phase A, members will obtain various doses and schedules of oral ABBV-744 pill to detect Harmless dosing routine. Additional contributors are going to be enrolled for the recognized monotherapy dosign program. In Section B, participants will get oral ruxolitinib and ABBV-744 is going to be specified as "insert-on" therapy. In Segment C, members